Tp82. Tp082 Let It Be - Clinical Advances in Pulmonary Vascular Disease: Pah and Beyond 2021
DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3581
|View full text |Cite
|
Sign up to set email alerts
|

Pulmonary Hypertension in Anti-Synthetase Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Overall, most large cohorts that reported PH based on RHC estimated variable prevalence of 7.9 to 20%. 54,104,109,110 Reports of successful management of PH-associated ASyS have been inconsistent with several case reports documenting improvement in symptoms and hemodynamics upon treatment with PAH-specific therapies. 104,111 However, in the largest collection of patients with RHC diagnosed precapillary PH, where 19 patients were started on PAHspecific therapy, improvement was not seen.…”
Section: Pulmonary Vascular Diseasementioning
confidence: 99%
“…Overall, most large cohorts that reported PH based on RHC estimated variable prevalence of 7.9 to 20%. 54,104,109,110 Reports of successful management of PH-associated ASyS have been inconsistent with several case reports documenting improvement in symptoms and hemodynamics upon treatment with PAH-specific therapies. 104,111 However, in the largest collection of patients with RHC diagnosed precapillary PH, where 19 patients were started on PAHspecific therapy, improvement was not seen.…”
Section: Pulmonary Vascular Diseasementioning
confidence: 99%